-
Je něco špatně v tomto záznamu ?
Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study
AN. Frix, LG. Heaney, B. Dahlén, F. Mihaltan, S. Sergejeva, S. Popović-Grle, V. Sedlak, L. Lehtimäki, A. Bourdin, S. Korn, E. Zervas, Z. Csoma, D. Lúðvíksdóttir, M. Butler, GW. Canonica, I. Grisle, K. Bieksiene, A. Ten Brinke, P. Kuna, C. Chaves...
Status neindexováno Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2015
PubMed Central
od 2015
Europe PubMed Central
od 2015
Open Access Digital Library
od 2015-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2015
- Publikační typ
- časopisecké články MeSH
INTRODUCTION: Treatment with biologics for severe asthma is informed by international and national guidelines and defined by national regulating bodies, but how these drugs are used in real-life is unknown. MATERIALS AND METHODS: The European Respiratory Society (ERS) SHARP Clinical Research Collaboration conducted a three-step survey collecting information on asthma biologics use in Europe. Five geographically distant countries defined the survey questions, focusing on seven end-points: biologics availability and financial issues, prescription and administration modalities, inclusion criteria, continuation criteria, switching biologics, combining biologics and evaluation of corticosteroid toxicity. The survey was then sent to SHARP National Leads of 28 European countries. Finally, selected questions were submitted to a broad group of 263 asthma experts identified by national societies. RESULTS: Availability of biologics varied between countries, with 17 out of 28 countries having all five existing biologics. Authorised prescribers (pulmonologists and other specialists) also differed. In-hospital administration was the preferred deliverance modality. While exacerbation rate was used as an inclusion criterion in all countries, forced expiratory volume in 1 s was used in 46%. Blood eosinophils were an inclusion criterion in all countries for interleukin-5 (IL-5)-targeted and IL-4/IL-13-targeted biologics, with varying thresholds. There were no formally established criteria for continuing biologics. Reduction in exacerbations represented the most important benchmark, followed by improvement in asthma control and quality of life. Only 73% (191 out of 263) of surveyed clinicians assessed their patients for corticosteroid-induced toxicity. CONCLUSION: Our study reveals important heterogeneity in the use of asthma biologics across Europe. To what extent this impacts on clinical outcomes relevant to patients and healthcare services needs further investigation.
Department of Pulmonology Lithuanian University of Health Sciences Kaunas Lithuania
Department of Respiratory Medicine and Allergy Karolinska University Hospital Stockholm Sweden
Department of Respiratory Medicine Liège University Hospital Liège Belgium
Department of Respiratory Medicine Medical Center Leeuwarden Leeuwarden the Netherlands
Department of Respiratory Medicine University Hospital of Liège Liège Belgium
Faculty of Medicine University of Southampton Southampton UK
Institute of Technology University of Tartu Tartu Estonia
Latvian Association of Allergists Center of Tuberculosis and Lung Diseases Riga Latvia
National Institute of Pneumology M Nasta Bucharest Romania
National Korányi Institute of Pulmonology Budapest Hungary
NIHR Southampton Biomedical Research Centre Southampton UK
Personalized Medicine Asthma and Allergy Humanitas Clinical and Research Center IRCCS Milan Italy
PhyMedExp Univ Montpellier CNRS INSERM CHU Montpellier Montpellier France
Respiratory Medicine Department and Asthma Center Athens Chest Hospital Sotiria Athens Greece
Respiratory Research Unit Bispebjerg University Hospital Copenhagen Denmark
School of Medicine University College Dublin Dublin Ireland
St Vincent's University Hospital University College Dublin Dublin Ireland
The Clinic for Lung Diseases Jordanovac University Hospital Centre Zagreb Zagreb Croatia
Universitätsmedizin Mainz Mainz Germany
University Clinic of Medicine Cantonal Hospital Basel Liestal Switzerland
University Clinic of Respiratory and Allergic Diseases Golnik Slovenia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22031462
- 003
- CZ-PrNML
- 005
- 20230127131155.0
- 007
- ta
- 008
- 230119s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1183/23120541.00273-2022 $2 doi
- 035 __
- $a (PubMed)36299366
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Frix, Anne-Noelle $u Department of Respiratory Medicine, University Hospital of Liège, Liège, Belgium
- 245 10
- $a Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study / $c AN. Frix, LG. Heaney, B. Dahlén, F. Mihaltan, S. Sergejeva, S. Popović-Grle, V. Sedlak, L. Lehtimäki, A. Bourdin, S. Korn, E. Zervas, Z. Csoma, D. Lúðvíksdóttir, M. Butler, GW. Canonica, I. Grisle, K. Bieksiene, A. Ten Brinke, P. Kuna, C. Chaves Loureiro, NM. Nenasheva, Z. Lazic, S. Škrgat, D. Ramos-Barbon, J. Leuppi, B. Gemicioglu, A. Bossios, CM. Porsbjerg, EH. Bel, R. Djukanovic, R. Louis
- 520 9_
- $a INTRODUCTION: Treatment with biologics for severe asthma is informed by international and national guidelines and defined by national regulating bodies, but how these drugs are used in real-life is unknown. MATERIALS AND METHODS: The European Respiratory Society (ERS) SHARP Clinical Research Collaboration conducted a three-step survey collecting information on asthma biologics use in Europe. Five geographically distant countries defined the survey questions, focusing on seven end-points: biologics availability and financial issues, prescription and administration modalities, inclusion criteria, continuation criteria, switching biologics, combining biologics and evaluation of corticosteroid toxicity. The survey was then sent to SHARP National Leads of 28 European countries. Finally, selected questions were submitted to a broad group of 263 asthma experts identified by national societies. RESULTS: Availability of biologics varied between countries, with 17 out of 28 countries having all five existing biologics. Authorised prescribers (pulmonologists and other specialists) also differed. In-hospital administration was the preferred deliverance modality. While exacerbation rate was used as an inclusion criterion in all countries, forced expiratory volume in 1 s was used in 46%. Blood eosinophils were an inclusion criterion in all countries for interleukin-5 (IL-5)-targeted and IL-4/IL-13-targeted biologics, with varying thresholds. There were no formally established criteria for continuing biologics. Reduction in exacerbations represented the most important benchmark, followed by improvement in asthma control and quality of life. Only 73% (191 out of 263) of surveyed clinicians assessed their patients for corticosteroid-induced toxicity. CONCLUSION: Our study reveals important heterogeneity in the use of asthma biologics across Europe. To what extent this impacts on clinical outcomes relevant to patients and healthcare services needs further investigation.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Heaney, Liam G $u Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK
- 700 1_
- $a Dahlén, Barbro $u Respiratory Medicine Unit, Department of Medicine, Solna Campus, and Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden
- 700 1_
- $a Mihaltan, Florin $u National Institute of Pneumology M. Nasta, Bucharest, Romania
- 700 1_
- $a Sergejeva, Svetlana $u Institute of Technology, University of Tartu, Tartu, Estonia
- 700 1_
- $a Popović-Grle, Sanja $u The Clinic for Lung Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia
- 700 1_
- $a Sedlak, Vratislav $u Department of Pneumology, University Hospital and Charles University Faculty of Medicine, Hradec Kralove, Czech Republic
- 700 1_
- $a Lehtimäki, Lauri $u Allergy Centre, Tampere University Hospital, and Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland $1 https://orcid.org/0000000315864998
- 700 1_
- $a Bourdin, Arnaud $u PhyMedExp, Univ Montpellier, CNRS, INSERM, CHU Montpellier, Montpellier, France $1 https://orcid.org/0000000246455209
- 700 1_
- $a Korn, Stephanie $u Universitätsmedizin Mainz, Mainz, Germany
- 700 1_
- $a Zervas, Eleftherios $u Respiratory Medicine Department and Asthma Center, Athens Chest Hospital "Sotiria", Athens, Greece $1 https://orcid.org/0000000174364550
- 700 1_
- $a Csoma, Zsuzsanna $u National Korányi Institute of Pulmonology, Budapest, Hungary
- 700 1_
- $a Lúðvíksdóttir, Dora $u Department of Allergy, Respiratory Medicine and Sleep Landspitali University Hospital Reykjavik Iceland, University of Iceland, Reykjavik, Iceland
- 700 1_
- $a Butler, Marcus $u St Vincent's University Hospital, University College Dublin, Dublin, Ireland $u School of Medicine, University College Dublin, Dublin, Ireland $1 https://orcid.org/0000000320267709
- 700 1_
- $a Canonica, Giorgio Walter $u Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Milan, Italy $1 https://orcid.org/0000000184672557
- 700 1_
- $a Grisle, Ineta $u Latvian Association of Allergists Center of Tuberculosis and Lung Diseases, Riga, Latvia
- 700 1_
- $a Bieksiene, Kristina $u Department of Pulmonology, Lithuanian University of Health Sciences, Kaunas, Lithuania
- 700 1_
- $a Ten Brinke, Anneke $u Department of Respiratory Medicine, Medical Center Leeuwarden, Leeuwarden, the Netherlands
- 700 1_
- $a Kuna, Piotr $u Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital Medical University of Lodz, Lodz, Poland
- 700 1_
- $a Chaves Loureiro, Claudia $u Pulmonology Department, Hospitais da Universidade de Coimbra, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
- 700 1_
- $a Nenasheva, Natalia M $u Department of Allergology and Immunology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia
- 700 1_
- $a Lazic, Zorica $u Faculty of Medical Sciences, University of Kragujevac, and Clinic for Pulmonology, Clinical Centre, Kragujevac, Serbia
- 700 1_
- $a Škrgat, Sabina $u University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia
- 700 1_
- $a Ramos-Barbon, David $u Respiratory Research Unit, Complexo Hospitalario Universitario & Instituto de Investigación Biomédica de A Coruña (INIBIC), Spain
- 700 1_
- $a Leuppi, Joerg $u University Clinic of Medicine, Cantonal Hospital Basel, Liestal, Switzerland $u University of Basel, Basel, Switzerland
- 700 1_
- $a Gemicioglu, Bilun $u Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey
- 700 1_
- $a Bossios, Apostolos $u Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden $1 https://orcid.org/0000000204942690
- 700 1_
- $a Porsbjerg, Celeste M $u Respiratory Research Unit, Bispebjerg University Hospital, Copenhagen, Denmark
- 700 1_
- $a Bel, Elisabeth H $u Department of Respiratory Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands
- 700 1_
- $a Djukanovic, Ratko $u Faculty of Medicine, University of Southampton, Southampton, UK $u NIHR Southampton Biomedical Research Centre, Southampton, UK
- 700 1_
- $a Louis, Renaud $u Department of Respiratory Medicine, Liège University Hospital, Liège, Belgium
- 773 0_
- $w MED00198703 $t ERJ open research $x 2312-0541 $g Roč. 8, č. 4 (2022)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36299366 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230119 $b ABA008
- 991 __
- $a 20230127131147 $b ABA008
- 999 __
- $a ok $b bmc $g 1889502 $s 1182795
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2022 $b 8 $c 4 $e 20221024 $i 2312-0541 $m ERJ open research $n ERJ Open Res $x MED00198703
- LZP __
- $a Pubmed-20230119
